Dermata Therapeutics (DRMA) Expected to Announce Earnings on Tuesday

Posted by Stanley Muller on Aug 11th, 2026

Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) is anticipated to announce its Q2 2026 results before the market opens on Tuesday, August 18th. Analysts expect Dermata Therapeutics to post earnings of ($0.55) per share for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.05.

Dermata Therapeutics Stock Up 1.8%

NASDAQ DRMA opened at $1.12 on Tuesday. Dermata Therapeutics has a 52 week low of $0.95 and a 52 week high of $6.58. The firm has a 50 day moving average of $1.25 and a two-hundred day moving average of $1.37. The stock has a market capitalization of $4.50 million, a PE ratio of -0.21 and a beta of 0.66.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Dermata Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Dermata Therapeutics has a consensus rating of “Hold” and an average target price of $10.00.

Get Our Latest Research Report on Dermata Therapeutics

Institutional Investors Weigh In On Dermata Therapeutics

An institutional investor recently bought a new position in Dermata Therapeutics stock. Clear Street Group Inc. bought a new position in shares of Dermata Therapeutics, Inc. (NASDAQ:DRMA – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 17,000 shares of the company’s stock, valued at approximately $39,000. Clear Street Group Inc. owned 0.60% of Dermata Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 8.67% of the stock is currently owned by institutional investors and hedge funds.

Dermata Therapeutics Company Profile

(Get Free Report)

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.